The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The potential association of plasma venetoclax level with treatment efficacy in first-line AML
In this video, Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, provides insight into the VENETACIBLE study (NCT06030089), which aimed to evaluate the relationship between plasma venetoclax levels, treatment response, and BCL2 expression in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy and treated with azacitidine-venetoclax (aza-ven) in the frontline setting. Dr Cluzeau highlights significant heterogeneity in plasma venetoclax levels across patients and suggests that personalized dosing of venetoclax may be necessary to maximize the efficacy of the aza-ven regimen in this patient population. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the VENETACIBLE study was presented here in poster presentation. So this is a study we performed between Nice and Marseille in France. So we decided to dose Venetoclax at day nine during cycle one for several patients, 20 patients treated by Azacitidine plus Venetoclax in first line for acute myeloid leukemia not eligible to intensive chemotherapy in our two centers, Nice and Marseille...
So the VENETACIBLE study was presented here in poster presentation. So this is a study we performed between Nice and Marseille in France. So we decided to dose Venetoclax at day nine during cycle one for several patients, 20 patients treated by Azacitidine plus Venetoclax in first line for acute myeloid leukemia not eligible to intensive chemotherapy in our two centers, Nice and Marseille. And what we identified, we identified a very great heterogeneity with the same given dose to the patients. We identified a very great heterogeneity in terms of the dosage of Venetoclax in the plasma and this heterogeneity was correlated to the efficacy of the Venetoclax in vitro, evaluated by Phospho-BCL2 by flow cytometry. So the hypothesis based on these few results, only 20 patients evaluated in this study, is that maybe there is a heterogeneity in each patient, because these are elderly patients, and maybe we could use the dosage of Venetoclax to personalize the dose of Venetoclax for each patient, maybe decrease the dose for some patients, but maybe also for a few patients, increase the dose to obtain an efficiency, the maximum, the maximal efficiency of Azacitidine plus Venetoclax for patients treated for AML, ineligible to intensive chemotherapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
